Abstract:The Glucagon-like peptide 1 receptor (GLP-1R) is a class B1 G-protein-coupled receptor (GPCR) that is widely expressed and helps mediate insulin secretion, gastric emptying, and satiety. Currently, GLP-1R peptide agonists are used as standard of care for the treatment of T2DM and more recently for obesity. These GLP-1R peptide agonists require frequent subcutaneous injections or strict dosing guidelines thus increasing the need to develop an oral small-molecule GLP-1R agonist. Here we describe the identification of a novel small molecule GLP-1R agonist (GS-4571) which stimulated a potent cAMP response in pancreatic β-cells (EndoC-BH1) and selective agonism against human and monkey GLP-1R versus other class B GPCRs. In an intraperitoneal glucose tolerance test (IPGTT) it demonstrated improved glucose tolerance in humanized GLP-1R mice. Further studies, in obese cynomolgus monkeys, GS-4571 demonstrated similar improvements in glucose tolerance after a single dose treatment. Once-daily oral administration of GS-4571 in obese diabetic cynomolgus monkeys not only showed improved glycemic control but also showed a reduction in energy intake which led to an increase in weight loss over 36 days. Together these data support the continued development of GS-4571 into the clinic as a novel orally bioavailable GLP-1R small molecule agonist. Disclosure J. Vogel: None. M. Seung: None. B. Marchand: Employee; Gilead Sciences, Inc. Stock/Shareholder; Gilead Sciences, Inc., Pfizer Inc., Arrowhead Pharmaceuticals, Inc., Kronos Bio, Inc., Allogene Therapeutics, Inc., AbCellera Biologics Inc., Arbutus Biopharma Corporation. N. Bhangre: Employee; Gilead Sciences, Inc. Research Support; Gilead Sciences, Inc. Stock/Shareholder; Gilead Sciences, Inc. J. Mukherjee: None. S.E. Ammann: Employee; Gilead Sciences, Inc. M. Armstrong: Employee; Gilead Sciences, Inc. G. Brizgys: Employee; Gilead Sciences, Inc. E. Chin: Employee; Gilead Sciences, Inc. C. Chou: None. J. Cottell: Employee; Gilead Sciences, Inc. S.D. Schroeder: Employee; Gilead Sciences, Inc. R. Thomas-Tran: Employee; Gilead Sciences, Inc. Z. Yang: None. M. Peters: Employee; Gilead Sciences, Inc. G. Budas: Employee; Gilead Sciences, Inc. M.L. Mitchell: Employee; Gilead Sciences, Inc. M. Chojnacka: None. S. Jermain: None. J. Hung: Employee; Gilead Sciences, Inc. S. Kulkarni: None. Q. Yue: None. D.W. Lin: Employee; Gilead Sciences, Inc. D.A. Miranda: None.

Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1h)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Discovery of Pyrrolidine-Containing Gpr40 Agonists: Stereochemistry Effects A Change in Binding Mode

Optimization of GPR40 Agonists for Type 2 Diabetes.

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1h-pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1 H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1h-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes.

Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.

Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Discovery of Novel Potent GPR40 Agonists Containing Imidazo[1,2-A]pyridine Core As Antidiabetic Agents.

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Discovery of Benzofuran Propanoic Acid GPR120 Agonists: from Uhts Hit to Mechanism-Based Pharmacodynamic Effects.

AMG 837: a potent, orally bioavailable GPR40 agonist.

Discovery of the Imidazole-Derived Gpr40 Agonist Am-3189

Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Design and Biological Evaluation of Tetrahydropyridine Derivatives As Novel Human GPR119 Agonists

Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.

1625-P: GS-4571, an Oral Small Molecule GLP-1R Agonist, Improves Glucose Tolerance and Suppresses Food Intake in Obese Diabetic Cynomolgus Monkeys

93-LB: Discovery of ID110521156, a Small Molecule GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes and Obesity